Long-acting interferon for myeloproliferative neoplasms - an update
S. Pai,J. Kaplan,F. Giles
DOI: https://doi.org/10.1080/17474086.2016.1231571
2016-09-13
Expert Review of Hematology
Abstract:Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells, in which one or more of the myeloid lineages are involved. Targeted tyrosine kinase inhibitors have revolutionized the management of chronic myeloid leukemia, an MPN driven by the BCR-ABL1 gene rearrangement, also known as the Philadelphia chromosome [1]. Polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), which constitute BCR-ABL1-negative MPNs, have relatively limited targeted therapeutic options. Ruxolitinib (Jakafi, Incyte Corporation, Wilmington, DE, USA), an orally bioavailable Janus-associated kinase (JAK) inhibitor, was approved by the US FDA in 2011 for the treatment of patients with intermediateand high-risk MF, including primary MF, post-PV MF, and post-ET MF [2], and in 2015 for PV patients who have had an inadequate response to or intolerance to hydroxyurea (HU) [3]. Traditional treatment for MPN is centered on managing symptoms, reducing burden of disease, preventing complications such as thrombosis, and maintaining hematological parameters within reasonable normalcy by using cytoreductive agents such as HU. The immunomodulatory cytokine interferon-alpha (IFN-α) is an emerging disease-modifying agent in MPNs, especially with the advent of highly effective, long-acting formulations with improved side-effect profiles. IFN-α-2b was first introduced in the treatment for Philadelphia-negative (Ph-neg) chronic myeloproliferative disorders almost three decades ago [4,5]. Preclinical data in mice model support that IFN preferentially depletes Jak2V617F MPN-propagating stem cells by activating cell cycle and promoting a predetermined erythroid-lineage differentiation program [6]. This was later shown to occur in humans by Prchal [7]. Several single-arm studies since then have demonstrated excellent outcomes, particularly for PV and ET, with responses in excess of 80% [8]. In early MF, IFNs can retard disease progression and reverse marrow changes [9]. These shortacting IFN regimes came at the cost of inconvenient treatment schedules, varying from once-daily treatment to three times weekly for periods of several months to a year or longer. Even though the dose of IFN required to treat MPN is low compared to that of other malignancies such as melanoma, toxicities are still a concern. Some of the earlier studies of IFN-α-2b in MPNs used higher than currently recommended doses that caused toxicities and early treatment discontinuation in about 20% of the patients. The pegylation of IFN, a process in which IFN is coupled to polyethylene glycol (PEG), inhibits proteolytic breakdown and clearance and, thereby increasing its half-life, allows for a decreased frequency of administration and possibly better tolerability and adherence. Several long-acting formulations such as peg–IFN-α-2b (PEG-IntronTM Schering Corporation, Kenilworth, NJ, USA), peg–IFN-α-2a (PEGASYS®, GenentechRoche, South San Francisco, CA, USA), and the more recent ultra-long-acting ropeginterferon-α-2b (AOP Orphan Pharmaceuticals, Vienna, Austria) have been licensed and evaluated in clinical trials. Peg–IFN-α-2b and IFN-α-2a are administered subcutaneously weekly, while ropeginterferon-α-2b can be administered once every 2 weeks. In spite of the perceived advantages of long-acting IFN, the only study that compared IFN-α-2b to peg–IFN-α-2b in the treatment of patients with newly diagnosed chronic-phase CML showed clinically comparable response rate and safety profile [10]. Peg–IFN-α-2b effectively reduced platelet counts in 29 of 42 patients in a phase 2 study in patients with PV and ET, but only 19 patients maintained a complete response (CR) at 2 years [11]. Normalization of neutrophil polycythemia rubra vera 1 (PRV-1) messenger RNA overexpression was noted in 36% (5 of 14 patients who had initially overexpressed PRV-1), suggesting that PEG–IFN may have an effect on the malignant clone. Adverse events (AEs) were the cause for discontinuation of therapy in 16 of 23 patients (70%), and the predominant AEs were fatigue (26%), muscle pain (13%), and headache (9%). Flu-like symptoms, depression, erythema, hair loss, and tachycardia were other causes that led to treatment discontinuation. In patients who were able to continue therapy, these differences abated with time, and at the 24-month assessment, their quality of life was not different from baseline. In a phase 2 multicenter study of peg–IFN-α-2a of 40 PV patients, hematologic responses were observed in the 37 evaluable patients, including 94.6% CRs at 12 months [12]. This treatment regimen was better tolerated, with only three patients (8%) discontinuing the treatment. After the first year, 35 patients remained in hematologic CR, including five who had stopped peg–IFN-α-2a. No vascular events were recorded.